Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Kidney Cancer | Research

Multiphase CT radiomics nomogram for preoperatively predicting the WHO/ISUP nuclear grade of small (< 4 cm) clear cell renal cell carcinoma

Authors: Yankun Gao, Xia Wang, Xiaoying Zhao, Chao Zhu, Cuiping Li, Jianying Li, Xingwang Wu

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Small (< 4 cm) clear cell renal cell carcinoma (ccRCC) is the most common type of small renal cancer and its prognosis is poor. However, conventional radiological characteristics obtained by computed tomography (CT) are not sufficient to predict the nuclear grade of small ccRCC before surgery.

Methods

A total of 113 patients with histologically confirmed ccRCC were randomly assigned to the training set (n = 67) and the testing set (n = 46). The baseline and CT imaging data of the patients were evaluated statistically to develop a clinical model. A radiomics model was created, and the radiomics score (Rad-score) was calculated by extracting radiomics features from the CT images. Then, a clinical radiomics nomogram was developed using multivariate logistic regression analysis by combining the Rad-score and critical clinical characteristics. The receiver operating characteristic (ROC) curve was used to evaluate the discrimination of small ccRCC in both the training and testing sets.

Results

The radiomics model was constructed using six features obtained from the CT images. The shape and relative enhancement value of the nephrographic phase (REV of the NP) were found to be independent risk factors in the clinical model. The area under the curve (AUC) values for the training and testing sets for the clinical radiomics nomogram were 0.940 and 0.902, respectively. Decision curve analysis (DCA) revealed that the radiomics nomogram model was a better predictor, with the highest degree of coincidence.

Conclusion

The CT-based radiomics nomogram has the potential to be a noninvasive and preoperative method for predicting the WHO/ISUP grade of small ccRCC.

Available only for authorised users

Hock L, Lynch J, Balaji K. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57–60. https://doi.org/10.1097/00005392-200201000-00015.CrossRefPubMed

Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, et al. NCCN Guidelines Insights: kidney Cancer, Version 2.2020. J Natl Compr Canc Netw. 2019;17:1278–85. https://doi.org/10.6004/jnccn.2019.0054.CrossRefPubMed

Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008;179:2131–5. https://doi.org/10.1016/j.juro.2008.01.097.CrossRefPubMed

Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and end results program. J Urol. 2006;176:2397–400. https://doi.org/10.1016/j.juro.2006.07.144. discussion 2400.CrossRefPubMed

Wong MCS, Goggins WB, Yip BHK, Fung FDH, Leung C, Fang Y, et al. Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep. 2017;7:15698. https://doi.org/10.1038/s41598-017-15922-4.CrossRefPubMedPubMedCentral

Hollingsworth J, Miller D, Daignault S, Hollenbeck B. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4. https://doi.org/10.1093/jnci/djj362.CrossRefPubMed

Rendon RA, Jewett MA. Expectant management for the treatment of small renal masses. Urol Oncol. 2006;24:62–7. https://doi.org/10.1016/j.urolonc.2005.07.003.CrossRefPubMed

Schieda N, Krishna S, Pedrosa I, Kaffenberger SD, Davenport MS, Silverman SG. Active surveillance of renal masses: the role of Radiology. Radiology. 2022;302:11–24. https://doi.org/10.1148/radiol.2021204227.CrossRefPubMed

Pahernik S, Ziegler S, Roos F, Melchior SW, Thuroff JW. Small renal tumors: correlation of clinical and pathological features with tumor size. J Urol 2007; 178:414–417; discussion 416–417. https://doi.org/10.1016/j.juro.2007.03.129.

10.

Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182:41–5. https://doi.org/10.1016/j.juro.2009.02.128.CrossRefPubMedPubMedCentral

11.

Moch H, Cubilla A, Humphrey P, Reuter V, Ulbright T. The 2016 WHO classification of Tumours of the urinary system and male genital Organs-Part A: renal, Penile, and testicular tumours. Eur Urol. 2016;70:93–105. https://doi.org/10.1016/j.eururo.2016.02.029.CrossRefPubMed

12.

Volpe A, Mattar K, Finelli A, Kachura JR, Evans AJ, Geddie WR, et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J Urol. 2008;180:2333–7. https://doi.org/10.1016/j.juro.2008.08.014.CrossRefPubMed

13.

Harris CR, Whitson JM, Meng MV. Under-grading of < 4 cm renal masses on renal biopsy. BJU Int. 2012;110:794–7. https://doi.org/10.1111/j.1464-410X.2012.10944.x.CrossRefPubMed

14.

Sasaguri K, Takahashi N, Gomez-Cardona D, Leng S, Schmit GD, Carter RE, et al. Small (< 4 cm) renal Mass: differentiation of Oncocytoma from Renal Cell Carcinoma on Biphasic contrast-enhanced CT. AJR Am J Roentgenol. 2015;205:999–1007. https://doi.org/10.2214/AJR.14.13966.CrossRefPubMed

15.

Takahashi N, Leng S, Kitajima K, Gomez-Cardona D, Thapa P, Carter RE, et al. Small (< 4 cm) renal masses: differentiation of Angiomyolipoma without visible Fat from Renal Cell Carcinoma using unenhanced and contrast-enhanced CT. AJR Am J Roentgenol. 2015;205:1194–202. https://doi.org/10.2214/AJR.14.14183.CrossRefPubMed

16.

Choi SY, Sung DJ, Yang KS, Kim KA, Yeom SK, Sim KC, et al. Small (< 4 cm) clear cell renal cell carcinoma: correlation between CT findings and histologic grade. Abdom Radiol (NY). 2016;41:1160–9. https://doi.org/10.1007/s00261-016-0732-9.CrossRefPubMed

17.

Orlhac F, Frouin F, Nioche C, Ayache N, Buvat I. Validation of a method to compensate Multicenter Effects affecting CT Radiomics. Radiology. 2019;291:53–9. https://doi.org/10.1148/radiol.2019182023.CrossRefPubMed

18.

Lambin P, Leijenaar R, Deist T, Peerlings J, de Jong E, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62. https://doi.org/10.1038/nrclinonc.2017.141.CrossRefPubMed

19.

Gillies R, Kinahan P, Hricak H, Radiomics. Images are more than pictures. They Are Data Radiology. 2016;278:563–77. https://doi.org/10.1148/radiol.2015151169.CrossRefPubMed

20.

Qu W-F, Tian M-X, Qiu J-T, Guo Y-C, Tao C-Y, Liu W-R, et al. Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning. Front Oncol. 2022;12. https://doi.org/10.3389/fonc.2022.968202.

21.

Zhang J, Wu Q, Yin W, Yang L, Xiao B, Wang J, et al. Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2023;23:431. https://doi.org/10.1186/s12885-023-10817-2.CrossRefPubMedPubMedCentral

22.

Uhlig J, Biggemann L, Nietert MM, Beissbarth T, Lotz J, Kim HS, et al. Discriminating malignant and benign clinical T1 renal masses on computed tomography: a pragmatic radiomics and machine learning approach. Med (Baltim). 2020;99:e19725. https://doi.org/10.1097/MD.0000000000019725.CrossRef

23.

Feng Z, Rong P, Cao P, Zhou Q, Zhu W, Yan Z, et al. Machine learning-based quantitative texture analysis of CT images of small renal masses: differentiation of angiomyolipoma without visible fat from renal cell carcinoma. Eur Radiol. 2018;28:1625–33. https://doi.org/10.1007/s00330-017-5118-z.CrossRefPubMed

24.

Haji-Momenian S, Ricker R, Chen Z, Houser M, Adusumilli N, Yang M, et al. Prediction of histologic grade and type of small (< 4 cm) papillary renal cell carcinomas using texture and neural network analysis: a feasibility study. Abdom Radiol (NY). 2021;46:4266–77. https://doi.org/10.1007/s00261-021-03044-5.CrossRefPubMed

25.

Yang R, Wu J, Sun L, Lai S, Xu Y, Liu X, et al. Radiomics of small renal masses on multiphasic CT: accuracy of machine learning-based classification models for the differentiation of renal cell carcinoma and angiomyolipoma without visible fat. Eur Radiol. 2020;30:1254–63. https://doi.org/10.1007/s00330-019-06384-5.CrossRefPubMed

26.

Scrima AT, Lubner MG, Abel EJ, Havighurst TC, Shapiro DD, Huang W, et al. Texture analysis of small renal cell carcinomas at MDCT for predicting relevant histologic and protein biomarkers. Abdom Radiol (NY). 2019;44:1999–2008. https://doi.org/10.1007/s00261-018-1649-2.CrossRefPubMed

27.

Chen S, Jiang L, Gao F, Zhang E, Wang T, Zhang N, et al. Machine learning-based pathomics signature could act as a novel prognostic marker for patients with clear cell renal cell carcinoma. Br J Cancer. 2022;126:771–7. https://doi.org/10.1038/s41416-021-01640-2.CrossRefPubMed

28.

Zhu YH, Wang X, Zhang J, Chen YH, Kong W, Huang YR. Low enhancement on multiphase contrast-enhanced CT images: an independent predictor of the presence of high tumor grade of clear cell renal cell carcinoma. AJR Am J Roentgenol. 2014;203:W295–300. https://doi.org/10.2214/AJR.13.12297.CrossRefPubMed

29.

Kar RK, Hanner AS, Starost MF, Springer D, Mastracci TL, Mirmira RG, et al. Neuron-specific ablation of eIF5A or deoxyhypusine synthase leads to impairments in growth, viability, neurodevelopment, and cognitive functions in mice. J Biol Chem. 2021;297:101333. https://doi.org/10.1016/j.jbc.2021.101333.CrossRefPubMedPubMedCentral

30.

Ding J, Xing Z, Jiang Z, Chen J, Pan L, Qiu J, et al. CT-based radiomic model predicts high grade of clear cell renal cell carcinoma. Eur J Radiol. 2018;103:51–6. https://doi.org/10.1016/j.ejrad.2018.04.013.CrossRefPubMed

31.

Halefoglu AM, Ozagari AA. Tumor grade estimation of clear cell and papillary renal cell carcinomas using contrast-enhanced MDCT and FSE T2 weighted MR imaging: radiology-pathology correlation. Radiol Med. 2021;126:1139–48. https://doi.org/10.1007/s11547-021-01350-y.CrossRefPubMed

32.

Xv Y, Lv F, Guo H, Liu Z, Luo D, Liu J, et al. A CT-Based Radiomics Nomogram Integrated with Clinic-Radiological features for Preoperatively Predicting WHO/ISUP Grade of Clear Cell Renal Cell Carcinoma. Front Oncol. 2021;11:712554. https://doi.org/10.3389/fonc.2021.712554.CrossRefPubMedPubMedCentral

33.

Haji-Momenian S, Lin Z, Patel B, Law N, Michalak A, Nayak A, et al. Texture analysis and machine learning algorithms accurately predict histologic grade in small (< 4 cm) clear cell renal cell carcinomas: a pilot study. Abdom Radiol (NY). 2020;45:789–98. https://doi.org/10.1007/s00261-019-02336-1.CrossRefPubMed

34.

Zhang T, Ming Y, Xu J, Jin K, Huang C, Duan M, et al. Radiomics and Ki-67 index predict survival in clear cell renal cell carcinoma. Br J Radiol. 2023;20230187. https://doi.org/10.1259/bjr.20230187.

35.

Ingels A, Hew M, Algaba F, de Boer OJ, van Moorselaar RJ, Horenblas S, et al. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. World J Urol. 2017;35:81–7. https://doi.org/10.1007/s00345-016-1854-y.CrossRefPubMed

36.

Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, et al. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncol Rep. 2022;47. https://doi.org/10.3892/or.2021.8234.

37.

Fang Z, Tang Y, Jiao W, Xing Z, Guo Z, Wang W, et al. Nitidine chloride induces apoptosis and inhibits tumor cell proliferation via suppressing ERK signaling pathway in renal cancer. Food Chem Toxicol. 2014;66:210–6. https://doi.org/10.1016/j.fct.2014.01.049.CrossRefPubMed

Title: Multiphase CT radiomics nomogram for preoperatively predicting the WHO/ISUP nuclear grade of small (< 4 cm) clear cell renal cell carcinoma
Authors: Yankun Gao
Xia Wang
Xiaoying Zhao
Chao Zhu
Cuiping Li
Jianying Li
Xingwang Wu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Computed Tomography
Computed Tomography
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11454-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling

Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial

Predictors of surgery choices in women with early-stage breast cancer in China: a retrospective study

Influence on therapeutic outcome of platelet count at diagnosis in patients with de novo non-APL acute myeloid leukemia

MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer